Ver­tex beefs up gene-edit­ing work with new dis­cov­ery pact; Ver­ri­ca shares jump on mol­lus­cum drug da­ta; J&J's inks two deals

→ Four months af­ter Ver­tex $VRTX and its al­lies at CRISPR Ther­a­peu­tics got start­ed on their first tri­al us­ing gene edit­ing tech for be­ta tha­lassemia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA